'Hot flush', an unpleasant symptom accompanying antiandrogen therapy of prostatic cancer and its treatment by cyproterone acetate

Int Urol Nephrol. 2000;32(1):77-9. doi: 10.1023/a:1007164319067.

Abstract

From 1995 to 1997 the authors have assessed 31 patients with histologically verified advanced carcinoma of the prostate (CaP) and the ensuing symptom of 'hot flush'. Patients underwent transurethral resection of the prostate (TURP), bilateral orchiectomy (OE) and combined androgen blockade (CAB) by the administration of non-steroid antiadrogens. The authors present the mechanism of the genesis of the 'hot flush' symptom as well as its subjective manifestations, methods of laboratory monitoring as well as their experience with the treatment of this symptom. 50 mg tablets cyproterone acetate administered twice daily or Androcur depot 300 mg i.m. inj. once in 14 days were the main factors in the treatment of 'hot flushes' which reduced subjective difficulties in 80.6% of the patients studied.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Androgen Antagonists / adverse effects*
  • Cyproterone Acetate / therapeutic use*
  • Hot Flashes / drug therapy*
  • Hot Flashes / etiology*
  • Humans
  • Male
  • Middle Aged
  • Orchiectomy / adverse effects*
  • Prostatectomy / adverse effects*
  • Prostatic Neoplasms / drug therapy*

Substances

  • Androgen Antagonists
  • Cyproterone Acetate